35212-22-7 | 3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$6.00	$4.00
100mg	98%	in stock	$8.00	$6.00
250mg	98%	in stock	$10.00	$7.00
1g	98%	in stock	$12.00	$9.00
5g	98%	in stock	$28.00	$19.00
25g	98%	in stock	$90.00	$63.00
100g	98%	in stock	$283.00	$198.00
500g	98%	in stock	$850.00	$595.00

Description

• Catalog Number: AB46292
• Chemical Name: 3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one
• CAS Number: 35212-22-7
• Molecular Formula: C18H16O3
• Molecular Weight: 280.3178
• MDL Number: MFCD00221719
• SMILES: CC(Oc1ccc2c(c1)occ(c2=O)c1ccccc1)C

Computed Properties

• Complexity: 407
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 3
• XLogP3: 4

Literature

• Why are most phospholipidosis inducers also hERG blockers?

  Archives of toxicology 20171201

• Mutagenicity of ipriflavone in vivo and in vitro.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120301

• Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study.

  Biomedical chromatography : BMC 20120101

• [Effect of ipriflavone on Wistar rats and their litters].

  Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 20120101

• Discovery of indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL).

  Journal of medicinal chemistry 20110428

• Identification of Hedgehog signaling inhibitors with relevant human exposure by small molecule screening.

  Toxicology in vitro : an international journal published in association with BIBRA 20100801

• Effects of ipriflavone on postmenopausal syndrome and osteoporosis.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20100201

• Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091208

• Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.

  European journal of medicinal chemistry 20090901

• [Effect of ipriflavone on growth and blood testosterone level in male rats].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20090501

• Determination of the anti-osteoporosis drug ipriflavone in pharmaceutical formulation by stripping voltammetric and chromatographic methods.

  Journal of AOAC International 20090101

• Effects of phytoestrogen on mitochondrial structure and function of hippocampal CA1 region of ovariectomized rats.

  Cellular and molecular neurobiology 20080901

• The combination of genistin and ipriflavone prevents mammary tumorigenesis and modulates lipid profile.

  Clinical nutrition (Edinburgh, Scotland) 20080801

• Effects of estrogen and estrogenic compounds on cognition in ovariectomized rats.

  Climacteric : the journal of the International Menopause Society 20080601

• Potential ipriflavone and warfarin interaction.

  The American journal of medicine 20071201

• Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes.

  Xenobiotica; the fate of foreign compounds in biological systems 20070301

• Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate.

  Biopharmaceutics & drug disposition 20061001

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats.

  The Journal of pharmacy and pharmacology 20060401

• Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males.

  Journal of the International Society of Sports Nutrition 20060101

• The effect of two dietary and a synthetic phytoestrogen on transepithelial calcium transport in human intestinal-like Caco-2 cells.

  European journal of nutrition 20050301

• Ipriflavone modulates IGF-I but is unable to restore bone in rats.

  Phytotherapy research : PTR 20050201

• Induction of apoptosis in cultured rat gastric epithelial cells by ipriflavone: comparison with indomethacin.

  Biological & pharmaceutical bulletin 20040501

• [Abnormality of bone mineral metabolism in type 2 diabetes mellitus].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• [Interaction between ipriflavone and other drugs in metabolism in vitro].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20040101

• Inhibition of COX isoforms by nutraceuticals.

  Journal of herbal pharmacotherapy 20040101

• Promoting effect of kaempferol on the differentiation and mineralization of murine pre-osteoblastic cell line MC3T3-E1.

  Bioscience, biotechnology, and biochemistry 20030601

• Use of alternative and complementary medicine in menopause.

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20021201

• Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model.

  International journal of cancer 20020801

• Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research.

  Urology 20020401

• [Comparative analyses on osteoporosis guidelines in Japan, EU and USA].

  Nihon rinsho. Japanese journal of clinical medicine 20020301

• Effects of ipriflavone on bone augmentation within a titanium cap in rabbit calvaria.

  Journal of oral science 20020301

• Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.

  Life sciences 20020201

• Clinical effects of phytoestrogens.

  Clinical obstetrics and gynecology 20011201

• Rapid improvement of osteomalacia by treatment in a case with Sjögren's syndrome, rheumatoid arthritis and renal tubular acidosis type 1.

  Internal medicine (Tokyo, Japan) 20010801

• Efficacy of ipriflavone in preventing adverse effects of leuprolide.

  The Journal of clinical endocrinology and metabolism 20010701

• Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.

  JAMA 20010321

• Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

  Endocrinology 19981001